T2	eligibility 583 685	Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor
T4	outcome-Measure 834 865	progression-free survival (PFS)
T5	total-participants 995 1013	One hundred thirty
T6	intervention-participants 1061 1063	64
T7	control-participants 1079 1081	66
T8	outcome 1146 1156	median PFS
T9	iv-cont-median 1160 1170	4.3 months
T10	cv-cont-median 1178 1188	2.3 months
T13	outcome 1335 1358	Median overall survival
T14	iv-cont-median 1404 1415	28.1 months
T15	cv-cont-median 1431 1442	19.8 months
T18	outcome 1495 1518	Fatigue and neutropenia
T19	outcome 1564 1589	Treatment discontinuation
T20	iv-bin-percent 1664 1667	11%
T21	cv-bin-percent 1670 1672	2%
T11	intervention 63 100	exemestane with or without entinostat
T1	outcome 1542 1562	grade 3/4 toxicities
T3	control 778 806	exemestane plus placebo (EP)
T12	outcome 1601 1615	adverse events
